PressOctober 8, 2021 Tryp Therapeutics To Collaborate With Researchers at The University of Wisconsin-Madison
PressOctober 7, 2021 Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial
PressOctober 6, 2021 PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
PressOctober 5, 2021 Lobe Sciences and the World Boxing Association Announce Initiative Targeting mTBI and PTSD
PressOctober 4, 2021 Cybin Announces Appointment of Dr. Amir Inamdar as Chief Medical Officer for European Operations and Dr. Geoff Varty as the Head of Research and Development
PressSeptember 29, 2021 HAVN Life Acquires Bennett’s Choice Patented Brain Health and Recovery Formulations
PressSeptember 28, 2021 BetterLife Pharma Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile
PressSeptember 27, 2021 MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy
PressSeptember 27, 2021 Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders
PressSeptember 24, 2021 MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration
PressSeptember 20, 2021 Mindset Pharma Announces Further Preclinical Results for its 5-MeO-DMT-Inspired Drug Candidate.
PressSeptember 20, 2021 Delic to Acquire Ketamine Wellness Centers Inc, Becoming Largest Psychedelic Wellness Chain in United States
PressSeptember 16, 2021 COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs
PressSeptember 16, 2021 Awakn Life Sciences to Acquire Leading Ketamine-assisted Psychotherapy Clinic in Norway
PressSeptember 15, 2021 Nova Mentis Life Science Applies to US FDA for Psilocybin Orphan Drug Designation Fragile X Syndrome Treatment
PressSeptember 15, 2021 Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
PressSeptember 14, 2021 Neuropsychiatry Expert Dr. Ilya Reznik (MD) Joins Cannabics as Head of Psychedelic Inspired Medicine
PressSeptember 13, 2021 PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
